Trial Profile
An open label, non-randomized, phase two trial in metastatic colorectal cancer (mCRC) with the combination of mFOLFIRI plus Aflibercept as first treatment: MINOAS trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MINOAS
- 15 Jun 2019 Primary endpoint (Overall Response Rate) has been met, as per results published in the Targeted Oncology.
- 15 Jun 2019 Results published in the Targeted Oncology
- 15 Jun 2019 Status changed from active, no longer recruiting to discontinued as per results published in the Targeted Oncology.